Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.

Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G.

Haematologica. 2011 Feb;96(2):333-6. doi: 10.3324/haematol.2010.031302. Epub 2010 Oct 15.

2.

Response to bortezomib and activation of osteoblasts in multiple myeloma.

Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G.

Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14. Review.

PMID:
17026821
3.

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.

Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G.

Br J Haematol. 2005 Oct;131(1):71-3.

PMID:
16173965
4.

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.

Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.

Br J Haematol. 2006 Dec;135(5):688-92.

PMID:
17107351
5.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.

Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G.

Eur J Haematol. 2011 Jun;86(6):484-7. doi: 10.1111/j.1600-0609.2011.01602.x.

6.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.

N Engl J Med. 2003 Jun 26;348(26):2609-17.

7.

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators.

Cancer. 2005 Mar 15;103(6):1195-200.

8.

Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.

Todisco E, Sarina B, Castagna L, Mazza R, Rahal D, Nozza A, Santoro A.

Leuk Lymphoma. 2007 May;48(5):1015-8. No abstract available.

PMID:
17487745
9.

Bortezomib: an effective agent in extramedullary disease in multiple myeloma.

Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E.

Eur J Haematol. 2006 May;76(5):405-8. Epub 2006 Mar 9.

PMID:
16529604
10.

[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].

Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Dec;14(6):1146-50. Chinese.

PMID:
17204182
11.

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA.

Int J Cancer. 2012 Sep 15;131(6):1466-71. doi: 10.1002/ijc.27342. Epub 2011 Dec 21.

12.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
13.

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.

Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA.

Leukemia. 2008 Dec;22(12):2247-56. doi: 10.1038/leu.2008.235. Epub 2008 Sep 4.

PMID:
18769451
14.

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

Richardson PG, Mitsiades C, Ghobrial I, Anderson K.

Curr Opin Oncol. 2006 Nov;18(6):598-608. Review.

PMID:
16988581
15.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J.

Br J Haematol. 2013 Mar;160(5):649-59. doi: 10.1111/bjh.12198. Epub 2013 Jan 7.

PMID:
23293914
16.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
17.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.

Br J Haematol. 2004 Oct;127(2):165-72.

PMID:
15461622
18.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.

N Engl J Med. 2005 Jun 16;352(24):2487-98.

19.

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ.

Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. Review.

PMID:
15056047
20.

Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.

Sadek I, Dispenzieri A, Gertz MA, Kumar S.

Leuk Lymphoma. 2009 Jun;50(6):1033-5. doi: 10.1080/10428190902919218. No abstract available.

PMID:
19455462

Supplemental Content

Support Center